期刊文献+

玻璃体腔内注射雷珠单抗注射液治疗特发性脉络膜新生血管的护理 被引量:5

下载PDF
导出
摘要 目的:总结玻璃体腔内注射雷珠单抗注射液治疗特发性脉络膜新生血管患者的护理方法。方法:对临床检查确诊的特发性脉络膜新生血管22例患者行玻璃体腔内注射雷珠单抗注射液,做好术前心理护理,注射时默契配合,加强并发症的观察,尤其是眼压、角膜上皮损伤、结膜下充血的监测。结果:本组22例患者22只眼中,末次随访视力提高16只眼。注射后次日眼压≥21 mmHg 3只眼,1 d后测眼压恢复正常;角膜上皮损伤1只眼,1周后检查时恢复正常;结膜下充血5只眼,1个月随访时均已吸收。随访期间未发生感染性眼内炎、玻璃体出血等并发症。结论:加强特发性脉络膜新生血管患者注射前、中、后护理,确保该注射的顺利是非常必要的。
作者 顾琪 陈琰
出处 《护理实践与研究》 2013年第18期74-75,共2页 Nursing Practice and Research
  • 相关文献

参考文献6

二级参考文献41

  • 1张美霞,严密,唐健,张军军,韦纯义,孟丹.光动力疗法治疗中心性渗出性脉络膜视网膜病变疗效观察[J].中华眼底病杂志,2007,23(1):17-20. 被引量:26
  • 2Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006, 355: 1419-1431. 被引量:1
  • 3Mitchell P, Korohelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol, 2010, 94:2-13. 被引量:1
  • 4LalloumF, Souied EH, Bastuj-Garin S, et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina, 2010, 30.. 399-406. 被引量:1
  • 5Inoue M, Kadonosono K, Watanabe Y, et al. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization. Retina, 2010,30 : 733-738. 被引量:1
  • 6Daniel P,Bernd K. Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity". Graefes Arch Clin Exp Ophthalmol, 2011, 249 : 631-632. 被引量:1
  • 7Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related maeular degeneration. Ophthalmology, 2007, 114: 246-252. 被引量:1
  • 8Fung AE, Lalwani GA, Roseufeld PJ, et al. An optical coherence tomoggraphy-guided variable dosing regimen with intravitreal Ranibizumab (Lucentis) for neovaseular age-related macular degeneration. Am J Ophthalmol, 2007, 143: 566-583. 被引量:1
  • 9Katz G, Giavedoni L, Muni K, et al. Effectiveness of 1 year of monthly versus variable-dosing intravitreal ranibizumab in thetreatment of choroidal neovascularization secendary to age- related macular degeneration[J/OL]. Retina, 2011, 31: E2060 [2011-09-16] http://www, ncbi. nlm. nih. gov/pubmed/ 21926941. [published online ahead of print]. 被引量:1
  • 10Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevaeizumab for neovascular age-related maeular degeneration. N Engl J Med, 2011,364 : 1897-1908. 被引量:1

共引文献21

同被引文献32

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部